Rituximab (chimeric anti-CD20 monoclonal antibodies) is currently being used in the treatment of B non-Hodgkin's lymphoma (NHL). We have recently reported that rituximab triggers and modifies various intracellular signaling pathways in NHL B-cell lines, resulting in reverting the chemoresistant phenotype to a sensitive phenotype. This study investigated whether rituximab also modifies intracellular signaling pathways resulting in the sensitization of NHL cells to Fas-induced apoptosis. Treatment of the Fas-resistant NHL cell lines (2F7, Ramos and Raji) with rituximab sensitized the cells to CH-11 (FasL agonist mAb)-induced apoptosis and synergy was achieved. Fas expression was upregulated by rituximab as early as 6 h post-treatment as determined by flow cytometry, reverse transcriptase-polymerase chain reaction and Western blot. Rituximab inhibited both the expression and activity of the transcription repressor Yin-Yang 1 (YY1) that negatively regulates Fas transcription. Inhibition of YY1 resulted in the upregulation of Fas expression and sensitization of the tumor cells to CH-11-induced apoptosis. The downregulation of YY1 expression was the result of rituximab-induced inhibition of both the p38 mitogen-activated protein kinase (MAPK) signaling pathway and constitutive nuclear factor j of B cells (NF-jB) activity. The involvement of NF-jB and YY1 in the regulation of Fas expression was corroborated by the use of Ramos cells with a dominant-active inhibitor of NF-jB (Ramos IjB-estrogen receptor (ER) mutant) and by silencing YY1 with YY1 siRNA, respectively. Further, the role of rituximab-mediated inhibition of the p38 MAPK/NF-jB/YY1 pathway in the regulation of Fas and sensitization to CH-11-induced apoptosis was validated by the use of specific chemical inhibitors of this pathway and which mimicked rituximab-mediated effects. These findings provide a novel mechanism of rituximabmediated activity by sensitizing NHL cells to Fas-induced apoptosis.
Introduction
Non-Hodgkin's lymphoma (NHL) includes a large group of neoplasms of the immune system representing a heterogeneous group of diseases that share the monoclonal expansion of both B and T cells. Up to 90% of NHL originate from B cells and represent a subpopulation of pre-B cells and a few mature B cells (Freedman and Nadler, 1991) . The incidence of NHL has been rising continuously for some years and NHL is now the fifth most common cancer.
Combination chemotherapy with R-CHOP (cyclophosphamide, doxorubicin, vincristine and prednisone) is the standard treatment option for aggressive NHL (Fisher et al., 1993) . However, only 40% of patients with aggressive NHL are cured. The emergence of newer biologic therapies in recent years has expanded the range of treatment options in oncology. Treatment of patients with NHL with monoclonal antibodies (mAb) has provided an alternative approach to this malignant disease. Their use allows for targeting of cell surface markers, making them more specific than traditional chemotherapeutic approaches. Rituximab is a chimeric monoclonal antibody that specifically targets the CD20 antigen on the surface of normal and malignant human B cells (Reff et al., 1994) . Its primary use has been for the treatment of follicular and low-grade NHL, but in combination with chemotherapy, is now being approved for the treatment of relapsed and refractory indolent NHL .
Different mechanisms have been suggested for the in vivo effect of rituximab, such as complementdependent cytotoxicity (CDC) (Reff et al., 1994; Golay et al., 2001) , antibody-dependent cellular cytotoxicity (ADCC) (Reff et al., 1994; Kennedy et al., 2003) , direct apoptotic effects (Shan et al., 2000) and possible synergistic effects with chemotherapeutic agents (Alas et al., 2001; Emmanouilides et al., 2003; Jazirehi et al., 2003) . However, additional mechanisms associated with rituximab-mediated interference with intracellular signaling pathways have not been ruled out. For instance, the association of CD20 with protein tyrosine kinases (Deans et al., 1995) suggests a role in intracellular signaling; several investigators have demonstrated that, following ligation of CD20 with antibodies, molecular changes associated with apoptosis take place (Cragg and Glennie, 2004) . Using in vitro model systems, our laboratory has reported that rituximab can reverse the drug-resistant phenotype of NHL cell lines to a drugsensitive phenotype. This was mediated at least, in part, via the selective downregulation of B-cell leukemia 2 protein (Bcl-2) expression in AIDS-related NHL (ARL) (Alas et al., 2001) or Bcl-2-related gene (Bcl-xL) in non-ARL (Jazirehi et al., 2003) . In addition, we have demonstrated that rituximab downregulates p38 mitogen-activated protein kinase (MAPK) activity in ARL 2F7 cells that in turn inhibits the transcription factors nuclear factor k of B cells (NF-kB) and Sp transcription factor family (Sp1) . Recently, we have reported that rituximab inhibits both the Raf-1/MEK1/ 2/ERK1/2 and NF-kB pathway, resulting in the downregulation of Bcl-2 expression ). These findings demonstrate that rituximab interaction with CD20 triggers the cells and modifies intracellular signaling pathways that regulate cell survival and proliferation of NHL cells (reviewed by .
The demonstration that rituximab inhibited NF-kB activity in the AIDS-related 2F7 cells and other non-ARL NHL B cell lines suggests that certain genes regulated by NF-kB may also be inhibited by rituximab. For example, in ovarian carcinoma cells, inhibition of the transcription repressor Yin Yang 1 (YY1) downstream of NF-kB results in the upregulation of Fas expression and sensitization of the tumor cells to Fasinduced apoptosis. YY1 negatively regulates Fas transcription via its DNA association to the silencer region of the Fas promoter (Garban and Bonavida, 2001 ). Based on these findings, we hypothesized that rituximab-mediated inhibition of NF-kB in NHL B cells may also inhibit YY1 expression and activity, and lead to the upregulation of Fas expression and sensitization to Fas-induced apoptosis. This study was designed to test this hypothesis and the following were investigated: (1) Does rituximab regulate Fas expression and sensitize the cells to Fas-induced apoptosis? (2) Does rituximab-mediated inhibition of NF-kB result in inhibition of YY1 expression and YY1 DNA-binding activity? (3) Does inhibition of YY1 result in the augmentation of Fas-induced apoptosis like rituximab? (4) Does inhibition of the NF-kB signaling pathway (by overexpression of a dominantactive inhibitor of NF-kB) result in the upregulation of Fas and sensitization to Fas-induced apoptosis like rituximab? and (5) Do inhibitors of the p38 MAPK/ NF-kB/YY1 signaling pathways mimic rituximab-mediated effects?
Results

Rituximab sensitizes NHL B-cell lines to Fas-induced apoptosis
Recent findings demonstrated that rituximab treatment of B-NHL cell lines triggers the cells and inhibits survival signaling pathways and sensitizes drug-resistant cells to drug-induced apoptosis Jazirehi et al., 2004 . Thus, we examined whether rituximab also sensitizes cells to Fas-induced apoptosis. 2F7, Ramos and Raji B-NHL cell lines were treated with the predetermined optimal concentration of rituximab (20 mg/ml) for 18 h, and the cells were then treated with the FasL agonist antibody CH-11 (20 ng/ml) for an additional 18 h. The cells were then harvested and analysed for cell viability and apoptosis (propidium iodide (PI) and activated caspase-3) as described in Materials and methods. The NHL cell lines were resistant following treatment with either rituximab or CH-11 alone; however, treatment with combinations of rituximab and CH-11 resulted in significant cytotoxicity and apoptosis (Table 1) . A titration of CH-11 antibody was examined and the findings demonstrate that the extent of apoptosis was a function of the CH-11 concentration used. The cells exhibited differential sensitivity to CH-11 as significant apoptosis was achieved with CH-11 concentrations >10 ng/ml for 2F7 and Ramos and greater than 0.2 ng/ml for Raji ( Figure 1a) . The combination treatment of rituximab and CH-11 resulted in synergistic apoptotic activity as determined by isobologram analysis (Figure 1b) .
The sensitization by rituximab to Fas-induced apoptosis was not the result of signaling by the Fc fragment of rituximab with Fc receptors on the tumor cells. This was determined by the use of genetically engineered rituximab molecules in which the CH 2 domain was deleted (CH 2 À ) since CH 2 is responsible for binding to the Fc receptor (Canfield and Morrison, 1991) . CH 2 À rituximab, unlike rituximab, was devoid of mediating ADCC and CDC (data not shown). Treatment of the cells with CH 2 À rituximab resulted in similar sensitization to CH-11-induced apoptosis as rituximab (Figure 1c) . The specificity of rituximab-mediated sensitization of B-NHL cell lines to CH-11-induced apoptosis was corroborated with the failure of CD19 monoclonal antibody to sensitize the cells to CH-11-induced apoptosis (Figure 1d ).
The findings demonstrate that rituximab sensitizes several B-NHL cell lines to CH-11-induced apoptosis. Further, the results suggest that rituximab might have signaled the NHL cells, resulting in the modification of the Fas apoptotic signaling pathway, and hence facilitating CH-11-induced apoptosis.
Rituximab upregulates the expression of Fas in NHL B-cell lines
The mechanism of rituximab-induced sensitization of B-NHL cells to Fas-induced apoptosis was examined. Previous findings have demonstrated that treatment of ovarian and prostate carcinoma cell lines with inter-feron-g (IFN-g) or nitric oxide (NO) resulted in the upregulation of Fas expression and sensitization of the cells to Fas-induced apoptosis (Garban and Bonavida, 2001 ). Thus, we examined whether rituximab-mediated sensitization to CH-11-induced apoptosis in B-NHL cells correlated with the upregulation of Fas expression.
2F7, Ramos and Raji cells were treated with rituximab (20 mg/ml) for 12 h and were first examined for surface Fas expression by flow cytometry. Significant upregulation of surface Fas expression was observed in all three lines as assessed by an increase of the mean fluorescence intensity (MFI) (Figure 2a ) and histogram analysis and 20 ng/ml for 2F7 and Ramos and 0.1, 0.2 and 0.3 ng/ml for Raji). The cells were preincubated with rituximab (20 mg/ml) for 18 h and further incubated upon addition of CH-11 for 18 h. Active caspase-3 was determined by flow cytometry. The enhancement of apoptosis by combination of rituximab and CH-11 was statistically significant when compared with treatment with rituximab or CH-11 alone (*Po0.05, **Po0.01). Mean values and standard deviation were obtained from three independent experiments. (b) 2F7, Ramos and Raji cells were treated with different concentrations of CH-11 in combination with different concentrations of rituximab and were examined for synergy by isobologram analysis as described in the Materials and methods. The FIC represents the concentration yielding a percentage of cytotoxicity of 3575%, graphed as a percentage of single-agent concentrations alone yielding 3075%. The isobolograms are representative of three independent experiments. (c) 2F7 cells were treated as described above in (a) with medium, CH2 À rituximab (20 mg/ml), rituximab (20 mg/ml) or IgG (20 mg/ml) isotype control and apoptosis was measured. *Po0.05, **Po0.03. (d) 2F7 cells were treated as described in (a) above with medium, rituximab (20 mg/ml), anti-CD19 (20 mg/ml), or IGG (20 mg/ml) isotype control and apoptosis was measured. *Po0.05, **Po0.03 /ml) were left untreated or treated with an optical concentration of CH-11 (20 mg/ml), rituximab (20 mg/ml) or combination. Cytotoxicity determined by Trypan blue dye exclusion and apoptosis by PI and caspase-3 activity as described in Materials and methods. *Po0.05 ( Figure 2b ). Time kinetic analysis of Fas expression following rituximab treatment revealed that significant upregulation of surface Fas expression was first observed 6 h after rituximab treatment and remained upregulated up to 24 h (Figure 2c ). Similar time kinetics were also observed by reverse transcriptase-polymerase chain reaction (RT-PCR) analyses demonstrating that Fas mRNA is increased at 3 h, peaks at 6 h and declines thereafter (Figure 2d ). Total Fas protein expression was also detected by Western blot following rituximab treatment and was augmented at 6 h ( Figure 2e ). These findings demonstrate that rituximab upregulates cell surface, and total Fas expression in B-NHL cell lines, reaching a peak at 6 h post-treatment and declines thereafter at 24 h.
Involvement of NF-kB-induced inhibition by rituximab in the regulation of Fas expression and sensitization to Fas NF-kB has been implicated in cell survival and has been shown to regulate the expression of several antiapoptotic gene products (Mori et al., 2001) . Hence, Fasinduced sensitization by rituximab might have been regulated by NF-kB. Treatment of 2F7 cells with rituximab for 18 h resulted in significant inhibition of NF-kB . Time kinetic analysis demonstrated that rituximab-mediated inhibition of NF-kB was detected at 3 h ( Figure 3b ). The role of NF-kB-mediated inhibition by rituximab in the regulation of Fas expression and sensitization to Fas apoptosis was examined with the Ramos IkB-aestogen receptor (ER) cells (Lee et al., 1999) . These cells overexpress a chimeric fusion protein consisting of a dominant-negative IkB-a mutant fused to a mutated ER ligand-binding domain. The fused ER confers inducible activation of the mutant IkB-a gene upon exposure to the synthetic estrogen 4-hydroxytamoxifen (4-OHT), thus having a functional block in the NF-kB signaling pathway. Treatment of Ramos IkB-ER cells, like Ramos, with rituximab resulted in the upregulation of Fas expression. However, treatment with 4-OHT to inhibit IkB-a phosphorylation and NF-kB activity in the absence of rituximab resulted in significant augmentation of Fas expression similar to rituximab treatment (Figure 3c , left). Treatment with both rituximab and 4-OHT did not augment Fas expression compared to treatment with either rituximab or 4-OHT alone. The regulation of Fas expression by NF-kB correlated with CH-11-induced apoptosis; treatment with 4-OHT significantly sensitized the Ramos IkB-ER cells to CH-11-induced apoptosis in the absence of rituximab, and treatment with combination 4-OHT and rituximab did not augment apoptosis compared to each agent alone (Figure 3c , right). Treatment of Ramos with 4-OHT had no effect (data not shown).
These findings demonstrate that NF-kB activity negatively regulates Fas expression and sensitivity to CH-11-induced apoptosis in NHL cells. Further, inhibition of NF-kB by rituximab sensitizes the cells to CH-11-induced apoptosis. 
Rituximab-mediated inhibition of YY1 expression and activity
Previous findings in ovarian cancer have demonstrated that inhibition of NF-kB resulted in inhibition of the transcription repressor YY1 and YY1 was found to be, in large part, responsible for the negative regulation of Fas transcription and expression (Garban and Bonavida, 2001 ). Hence, since rituximab inhibited NF-kB activity, we examined the effect of rituximab treatment on YY1 expression and activity in 2F7 cells. The cells were treated with rituximab (20 mg/ml) for 24 h and total cell lysates and nuclear lysates were prepared. YY1 expression was downregulated following treatment with rituximab as demonstrated by flow cytometry (Figure 4a ) and Western blot (Figure 4b ). In addition, rituximab inhibited YY1 DNA-binding activity as assessed by EMSA (Figure 4c ). Since rituximab inhibits the Src kinase/p38 MAPK/NF-kB, YY1 inhibition was also observed with the Src kinase inhibitor PP2, the p38 MAPK inhibitor SB203580 and the NF-kB inhibitor Bay 11-7085 (Figure 4a-c) . Time kinetic analyses demonstrated that inhibition of YY1 DNA-binding activity was evident at 6 and 12 h and recovered partially at 24 h (Figure 4d ). These time kinetics were correlated with the kinetics of Fas expression (Figure 2 ). These findings demonstrate that rituximab downregulates YY1 expression and DNA-binding activity and inhibition of YY1 appears to be regulated by p38 MAPK and NFkB. The findings also suggest that upregulation of Fas expression by rituximab correlates with inhibition of the transcriptional repressor YY1.
Rituximab-mediated inhibition of NF-kB and YY1 via inhibition of phospho-p38 MAPK results in the upregulation of Fas and sensitization to CH-11-induced apoptosis
We have recently reported that rituximab inhibits the p38 MAPK signaling pathway in 2F7 cells, resulting in the downstream inhibition of both NF-kB and Sp1 transcription factors . We thus examined whether inhibition of the p38 MAPK pathway by rituximab was also responsible for inhibition of NFkB activity and subsequent inhibition of YY1 expression and activity. P38 MAPK is regulated upstream by Src kinases such as Lyn. Hence, total cell lysates from 2F7 cells treated with rituximab were examined for Lyn and p-Lyn, and for p38 MAPK and p-p38 MAPK by Western blot. Figure 5a demonstrates that while the basal levels of Lyn and p38 MAPK were unaffected by rituximab, significant inhibition of p-Lyn and p-p38 MAPK were observed by rituximab treatment. Time kinetic analyses demonstrated that rituximab treatment inhibited p-Lyn at 3 h and p-p38 MAPK at 6 h and inhibition was increased thereafter (Figure 5b ), similar to rituximab-induced inhibition of YY1 activity (Figure 4d ). The role of rituximab in the regulation of the Lyn/p38 MAPK pathway was corroborated by the use of Src kinase (PP2), p-38 MAPK (SB203580) and NF-kB (Bay 11-7085) chemical inhibitors (Figure 5a) . The above findings suggested that rituximabmediated inhibition of both the p38 MAPK pathway and downstream NF-kB and YY1 activities may also be involved in the sensitization of 2F7 cells to CH-11-induced apoptosis. Thus, inhibition of targets in this pathway by various inhibitors should mimic rituximabmediated effects and should result in the sensitization of cells to CH-11 apoptosis. This was tested by pretreatment of 2F7 cells with rituximab (20 mg/ml) or various inhibitors (PP2, SB2035801, Bay 11-7085, NO) for 5 h, and followed by treatment with CH-11 (20 ng/ml) for 18 h. The cells were then tested for apoptosis by DNA hypodiploidy assay and confirmed by evaluating the levels of active caspase-3 using flow cytometry. As depicted in Figure 6a , like rituximab, inhibitors of the Src kinase (PP2), p38 MAPK (SB203580), NF-kB (Bay 11-7085) and YY1 (NO) (Garban and Bonavida, 2001) or YY1 siRNA (Figure 4 ) all resulted in significant sensitization to CH-11-induced apoptosis albeit there were differences in the degree of apoptosis achieved by these inhibitors. The specificity of the p-38 MAPK pathway in sensitization to CH-11-induced apoptosis was revealed by the use of the MEK/ERK inhibitor PD 98059. Treatment of 2F7 with PD 98059 did not sensitize the cells to CH-11-induced apoptosis (Figure 6a ), nor did it upregulate Fas or inhibit YY1 expression (Figure 6b ). These findings demonstrate that rituximab-mediated inhibition of the p-Lyn/p38 MAPK/NF-kB/YY1 signaling pathway results in the sensitization of cells to CH-11-induced apoptosis.
Activation of caspase-9 in rituximab-induced sensitization to CH-11-induced apoptosis
We examined the apoptotic signaling pathway utilized by combination of rituximab and CH-11 in 2F7 cells. Caspase-8 activation was minimally activated by CH-11 and was not augmented by the combination of rituximab and CH-11. However, the combination treatment activated caspase-9 with little activation by CH-11 in the absence of rituximab (Figure 7a ). These findings suggested that the mitochondrial Type II pathway was involved (Barnhart et al., 2003) . This pathway was corroborated by demonstrating cytochrome c and second mitochondria-derived activator of caspase/direct inhibitor of apoptosis-binding protein with low PI (Smac/DIABLO) in the cytosol, which were released from the mitochondria following combination treatment. There was also poly-(ADP-ribose) poly- (Figure 7b ). These findings suggested that rituximab-induced sensitization to CH-11-induced apoptosis resulted from activation of the mitochondria pathway as a result of complementation by rituximab and CH-11.
Discussion
This study presents evidence for the first time that rituximab treatment of Fas-resistant B-NHL cell lines sensitizes the cells to Fas-induced apoptosis and synergy is achieved. Rituximab upregulates Fas expression by inhibiting NF-kB activity and both the expression and activity of the transcriptional repressor, YY1, which negatively regulates Fas transcription and expression. Rituximab-mediated inhibition of the p38 MAPK/NFkB/YY1 signaling was corroborated by the use of specific chemical inhibitors; inhibition of Src kinases, p-p38 MAPK, NF-kB and YY1 all mimicked rituximab treatment and resulted in the upregulation of Fas expression and sensitization of B-NHL cells to CH-11- induced apoptosis. The direct role of NF-kB inhibition by rituximab in the regulation of Fas and sensitization to CH-11-induced apoptosis was demonstrated in stable transfectants overexpressing mutant IkB-a. These findings reveal a novel mechanism of rituximab-mediated signaling, via NF-kB and YY1 inhibition, in the regulation of B-NHL cells to Fas-induced apoptosis.
The findings also suggest a potentially novel in vivo mechanism of rituximab-mediated effect that may be involved in the regulation of the clinical response of NHL patients to rituximab treatment. The present findings demonstrate that treatment of B-NHL cells with rituximab inhibits the p-38 MAPK/NFkB/YY1 signaling pathway, resulting in the upregulation of Fas expression and sensitization to Fas-induced apoptosis. Time kinetic analysis revealed that inhibition of this pathway begins at 3 h postrituximab treatment and thereafter inhibition is enhanced and corresponded with kinetics of Fas expression; Fas expression was augmented at 3 h, peaked at 6-12 h and decreased at 24 h postrituximab treatment.
Rituximab treatment of 2F7 cells downregulates both the expression and DNA-binding activity of YY1. Our recent findings in 2F7 cells have demonstrated that rituximab inhibits both the p-p38 MAPK and NF-kB pathways . We demonstrated in this study that the downregulation of p-p38 MAPK by rituximab is accompanied by inhibition of both NF-kB activity and inhibition of YY1 transcription and activity. Several lines of evidence support the role of NF-kB in the regulation of YY1 expression. We show that rituximab downregulates NF-kB activity concomitant with the downregulation of YY1 expression and activity. Further, inhibition of constitutive NF-kB in the Ramos IkB-ER mutant cells resulted in inhibition of YY1. Likewise, inhibition of NF-kB with the chemical inhibitor Bay 11-7085 resulted in inhibition of YY1. These findings demonstrate that rituximab-mediated inhibition of NF-kB activity is linked to the downregulation of p-p38 MAPK. p-p38 MAPK activity is regulated through the phosphorylation of IkB kinase complex (IKK), an NF-kB activator (Martin-Blanco, 2000) .
The functional role of rituximab-mediated inhibition of the p-p38 MAPK/NF-kB/YY1 signaling pathway in the regulation of Fas expression and sensitization to CH-11-induced apoptosis was shown by the use of specific chemical inhibitors of this pathway. Hence, inhibition of p-p38 MAPK by SB203580 and inhibition of NF-kB by Bay 11-7085 resulted in sensitization of B-NHL cells to CH-11-induced apoptosis. Further, the role of YY1 in sensitization to Fas was demonstrated by treatment of the cells with the NO donor, (Z)-1-[2-(aminoethyl)-N-(2-ammonio-ethyl_amino]diazen-1-ium-1,2-diolate (DETA-NONOate), which reacts chemically with YY1 and leads to nitrosation of YY1 and inhibition of its DNA-binding activity .
Previous findings revealed that treatment of ovarian and prostate carcinoma cell lines with IFN-g or NO resulted in the upregulation of Fas expression and sensitization of the tumor cells to Fas-induced apoptosis. It was found that NO inhibits the DNA-binding activity of the transcriptional repressor YY1, which negatively regulates Fas transcription. Three potential YY1-responsive elements were found to cluster in a very narrow sequence within the Fas promoter silencer region, between À1619 and À1533 bp relative to the transcription initiation site. Deletion of the silencer region of the Fas promoter in a reporter assay resulted in the augmentation of Fas expression of the tumors cells (Garban and Bonavida, 2001) . In the present study, we demonstrate that rituximab, like IFN-g and NO, downregulates YY1 expression and YY1 DNA-binding activity in B-NHL cells and these effects correlated with upregulation of Fas expression. The direct role of YY1 in the regulation of Fas expression was corroborated with prostate cancer cells transfected with siRNA YY1 (data not shown). Such transfectants exhibited upregulation of Fas expression and were sensitized to CH-11 and mimicked rituximab-mediated effects (Figure 4d) .
The apoptotic pathway involved in rituximabmediated sensitization of the B-NHL cells to Fasinduced apoptosis was examined. Treatment with rituximab alone did not have any effect on the activation of caspases or the mitochondria. Likewise, treatment with CH-11 resulted in minor activation of caspase-8 and caspase-9, which correlated with moderate induction of apoptosis. However, treatment with the combination of rituximab and CH-11 resulted in mitochondrial depolarization and release of cytochrome c and Smac/DIABLO and activation of caspase-9 and caspase-3 and PARP cleavage suggesting involvement of the Type II mitochondrial apoptotic pathway (Barnhart et al., 2003) . The activation of the mitochondrial Type II pathway by combination of rituximab and CH-11 may be due to the inhibition of the antiapoptotic gene product, Bcl-xL, by rituximab . Our finding here is in agreement with recent studies reported by Byrd et al. (2002) , who demonstrated that cells derived from chronic lymphocytic leukemia patients treated with rituximab showed apoptosis via the mitochondrial pathway, that is, activation of caspase-9 and caspase-3 but not caspase-8.
While rituximab treatment of NHL cell lines does not result in apoptosis, with some exceptions, crosslinking of rituximab by a secondary immunoglobulin G (IgG) antibody can result in apoptosis (Shan et al., 2000) . There was activation of protein tyrosine kinases, increase in the intracellular calcium and activation of caspases. While our in vitro findings require the FasL agonist CH-11 to induce apoptosis in rituximab-treated cells, such findings may have important consequences in the in vivo setting. For instance, rituximab-treated NHL cells may be sensitized by FasL-expressing host cells (T, NK, macrophages) and undergo apoptosis. Thus, we speculate that in the in vivo setting, rituximab may exert a new mechanism of action, namely the sensitization of NHL cells to host Fas-induced apoptosis. In contrast, the failure of certain patients to respond to rituximab may be due, in part, to failure to sensitize the tumor cells to immune-mediated apoptosis. Such failure may be due to mutation of Fas acquired by B-NHL cells and such cells become resistant to Fas induced apoptosis. About 20% of B-cell lymphoma derived from postgerminal center B cells were found to carry mutations or defects in the expression level of Fas (Li-Weber and Krammer, 2003) . Alternatively, based on our findings in vitro with the B-NHL cell lines, it is possible that the p38 MAPK/ NF-kB/YY1 signaling pathway is not modified by rituximab, and thus the cells will not be sensitized to Fas-induced apoptosis. These possibilities are currently under investigation.
In summary, the present study reveals a novel mechanism of rituximab-mediated signaling that results in the sensitization of B-NHL cells to immune-mediated apoptosis. Our findings are schematically diagrammed in Figure 8 activated Src kinases and p38 MAPK (Iida et al., 1999; Ogasawara et al., 2003) , which result in the activation of NF-kB. NF-kB regulates the transcription and activity of the transcriptional repressor YY1, which in turn negatively regulates the transcription of Fas. Hence, the activation of the Src/p38 MAPK/NF-kB/YY1 pathway regulates the resistance of the tumor cells to Fas-induced apoptosis (Figure 8a ). However, rituximab treatment of B-NHL cells inhibits the Src/p38 MAPK/NF-kB/YY1 pathway leading to the upregulation of Fas expression and sensitization to Fas-induced apoptosis. Rituximabmediated signaling was confirmed using specific chemical inhibitors, such as PP2 for Src, SB203580 for p38 MAPK, Bay 11-7085 for NF-kB and NO or siRNA for YY1, which result in the upregulation of Fas expression and sensitization of B-NHL cells to Fas-induced apoptosis (Figure 8b ). Our findings suggest that in addition to the reported ADCC, CDC and apoptosis attributed to rituximab (Shan et al., 2000) , sensitization to immune-induced apoptosis by rituximab may be one complementary mechanism of rituximab-mediated effect in vivo. In addition, this study identifies several novel intracellular targets induced by rituximab whose modifications may potentiate the effect of rituximab and/or substitute for rituximab in the treatment of rituximabresistant NHL.
Materials and methods
Cell lines and reagents
The NHL B-cell line 2F7 was derived from a patient suffering from AIDS with Burkitt's lymphoma and was kindly provided by Dr Otoniel Martinez-Maza (Jonsson Comprehensive Cancer Center, Los Angeles, CA, USA). 2F7 cells are currently available from the American Tissue Cell Collection (ATCC) (Manassas, VA, USA). The Ramos and Raji cell lines are of Burkitt's lymphoma origin and were purchased from ATCC. The prostate carcinoma cell line PC-3 cells were cultured in Petri dishes as described . Cultures were additionally supplemented with 1% bacteriofungicide solution containing 10 000 unit (U)/ml penicillin G, 10 mg/ml streptomycin and 25 mg/ml fungizone (Cellgro). Cells were cultured in 5% CO 2 at 371C. The Fas mAb used for immunoblotting was purchased from Dako (Carpinteria, CA, USA). The mAb, CH-11, was purchased from MBL (Woburn, MA, USA). Fas expression by flow cytometry was determined with mouse anti-human Fas mAb (IgG1 clone UB2) from MBL. Ramos IkB-a-ER mutant cells (Lee et al., 1999) were grown in RPMI 1640 medium (Mediatech, VA, USA) with 10% heat-inactivated fetal bovine serum (FBS) (Gibco, Co., Carlsbad, CA, USA). The cells were grown in the presence and absence of DETANONOate (1000 mM) . The DETANONOate was obtained from Alexis (San Diego, CA, USA).
The human Ramos B-cell line with a functional block in the NFkB signaling pathway Ramos IkB-a mutant was kindly provided by Dr Genhong Cheng (Lee et al., 1999) (UCLA), and was generated with the 5 0 -FLAG-tagged IkB mutant (with serine-to-alanine mutations at position 32 and 36) and was fused in-frame to the 5 0 of the mutant ER ligand-binding domain, and the chimera was cloned into pCDNA3 to generate the pCDNA3-IkB-ER construct. Ramos wild-type cells were transfected by electroporation with pulses at 250 V/ 975 mF. The overexpression of a chimeric fusion protein IkBmutant-ER has inducible activation upon exposure to the synthetic estrogen 4-OHT, (200 nM for 3 h). The 4-OHT was purchased from Calbiochem (San Diego, CA, USA).
Monoclonal anti-human CD20 antibody, rituximab (IDEC-C2B8)
Rituximab is a monoclonal antibody specific for human CD20 of mouse origin and genetically engineered to be chimeric, possessing an F(ab 0 )2 mouse fragment linked to a human Fc segment (Reff et al., 1994) . Rituximab was obtained commercially. The engineered rituximab with the CH 2 À deleted domain was used to examine the effect of crosslinking with the Fc receptors on the B cells. Rituximab (CH 2 À ) was kindly provided by Dr Paul Chinn from IDEC Pharmaceuticals Inc. (San Diego, CA, USA).
Flow cytometric analysis for apoptosis
Cytotoxicity was determined by Trypan blue dye exclusion and by both PI and activated caspase-3 by flow cytometry. Sensitization to Fas-mediated apoptosis was assessed using the anti-Fas antibody CH-11 (MBL) (10 mg/ml) in an 18 h incubation assay. Active caspase-3 was analysed by flow cytometry using a fluorescein isothiocyanate-conjugated antiactive caspase-3 monoclonal antibody (BD Pharmingen, San Diego, CA, USA). A total of 2 Â 10 6 cells/sample were distributed into a 12-well plate and incubated with rituximab (20 mg/ml) by 18 h and treated with CH-11 antibody for an additional 18 h. The cells were washed twice with phosphatebuffered saline (PBS)-FCS and stained intracellularly for active caspase-3 and the samples were analysed by flow cytometry. The gates were set in accordance with gates obtained with the isotype-matched control antibody. Population data were acquired on a Flow cytometer EPICS R XL-MCL (Coulter Co., Miami, FL, USA), with the System IIt Software and the percent positive cells were recorded. Tumor cells were stained with PI and analysed for DNA fragmentation as described previously (Alas et al., 2001) . Trypan blue dye exclusion was determined by microscopic examination.
FACS analysis for protein expression
Surface Fas antigen expression in tumor cells was determined by flow cytometry. Cells were treated for 3, 6, 12 and 24 h with rituximab (20 mg/ml) or medium alone. The cells were washed with cold buffer consisting of PBS without Ca 2 þ or Mg 2 þ with FCS 5 and 0.1% sodium azide. Surface expression was determined in cells (2 Â 10 6 ) that were pretreated with human AB serum (Cellgro) for 30 min. The cells were washed twice and resuspended in 50 ml of PBS. The cells were incubated with 10 mg/ml of monoclonal anti-Fas (MBL) for extracellular detection, or isotype control antibodies for 30 min. The cells were washed twice and incubated with anti-rabbit antibody PE-conjugated (Pharmingen, San Diego, CA, USA). The cells were washed twice and analysed by flow cytometry with an Epics-XL MCL flow cytometer (Coulter Inc., Miami, FL, USA).
Determination of Fas transcription by RT-PCR
RT-PCR was used to determine if the Fas regulation induced by rituximab was at the level of transcription. 2F7 cells (2 Â 10 6 ) were treated in 12-well plates (Costar, Cambridge, MA, USA) with rituximab (20 mg/ml) for 3, 6, 12 and 24 h at 371C in a 5% CO 2 incubator. Total RNA was extracted at specified time points using the single-step guanidinium thiocyanate-chloroform method with STAT 60 reagents (TelTest'B' Inc., Friendswood, TX, USA). RNA (2 mg) was reverse transcribed to first-stranded cDNA for 1 h at 421C using SuperScriptt II RNAase H reverse Transcriptase (Invitrogen Life Technologies, Carlsbad, CA, USA),and random hexamer primers (15 mM) (Invitrogen Life Technologies, Carlsbad, CA, USA). Amplification of these cDNA by PCR was performed using the following gene-specific primers: Fas receptor sense (5 0 -AAC ATG CAG AAA GCA CAG AAA GGA AA-3 0 ), Fas receptor antisense (5 0 -GAT CTC CAT CTA TTT TGG CTT CAT TGA CAC C-3 0 ) (196 bp expected product). Internal control for equal cDNA loading in each reaction was assessed using the following gene-specific glyceraldehyde-3-phosphate dehydrogenase primers: sense, 5 0 -GAA CAT CAT CCC TGC CTC TAC TG-3 0 ; and antisense, 5 0 GTT GCT GTA GCC AAA TTC GTT G-3 0 (355 bp expected product). PCR amplification was carried out using the Hot Start/Amplimax method as described , with the following temperature cycling parameters: 951C/60 s, 601C/ 60 s, 721C/3 min for 30 cycles, and a final extension at 721C/ 5 min.
Western blot analysis for protein expression
2F7 cells in medium with 10% FBS were treated with rituximab (20 mg/ml) and incubated at 371C for 3, 6, 12 and 24 h. Cell extracts for Fas expression analysis were prepared by lysing 2 Â 10 6 cells on ice with cold 200 ml of readioimmoprecipitation assay (buffer) (RIPA) buffer (1% NP40; octylphenoxypolyethoxyerthanol; polyethyleneglycol-p-isooctylphenyl ether (NP40), 0.1% sodium dodecyl sulfate (SDS), 0.5% deoxycholic acid, complete protease inhibitor cocktail tablets (Roche Diagnostic Co., Indianapolis, IN, USA) and 1 Â PBS). Lysates were transferred to microcentrifuge tubes and sonicated in SONICATORt, Model W-220F (Heat-System Ultrasonic Inc.) for 10 s. Lysates were centrifuged at 12 000 g at 41C for 5 min. Protein concentration was quantified using the Bio-Rad protein assay (Bio-Rad Laboratories, Hercules, CA, USA). Gel loading buffer Bio-Rad (Bio-Rad Laboratories) was added to the cell lysates at a 1 : 1 volume. The samples were boiled for 5 min and were separated on 12% SDS-polyacrylamide minigels and transferred to nitrocellulose membrane Hybondt ECLt (Amersham Pharmacia Biotech, Germany) in Trans-Blot s SD semidry Transfer cell System (Bio-Rad). Primary antibodies for CD95 (1 : 1000) (Santa Cruz Biotechnology) or Phospho-p38 (Cell Signaling Technology) were used. Nitrocellulose blots were developed by LumiGLO 
Treatment of 2F7 cells with inhibitors
The inhibitors SB203580, PP2 and Bay 11-7085 were obtained from Calbiochem (San Diego, CA, USA), and the solvent, dimethyl sulfoxide (DMSO) was purchased from Sigma Chemical Co. (St Louis, MO, USA). SB203580 (pyridinyl imidazol, potent inhibitor of p38 and p38b MAPKs) (Iwasaki et al., 1999) was added to the culture medium at a concentration of 10 mM, and the cells (1 Â 10 6 cells/ml) were pretreated for 1 h or incubated for 24 h at 371C with the inhibitor or with DMSO alone. The inhibitor PP2 (pyrazolopyrimidine-specific Src family kinase inhibitor; Hanke et al., 1996) was added at a concentration of 15 mM, and the cells were pretreated or incubated under the same conditions as above. The NF-kB inhibitor Bay 11-7085 (a specific inhibitor of IkBa (inhibitor of NF-kB) phosphorylation) (Pierce et al., 1997) was added at 6 mM under the same conditions. For detection of phosphorylated MAPK, the cells were cultured in 0.1% serum overnight before treatment.
Gel mobility shift assays
Briefly, 2F7 cells (10 6 ) were harvested after treatment and washed twice with cold Dulbecco's PBS (Cellgro). After washing, the cells were lysed in 1 ml of NP40 lysis buffer (10 mM Tris-HCl, pH 7.5, 10 mM NaCl, 3 mM MgCl 2 and 0.5% NP40) on ice for 5 min. Samples were centrifuged at 300 g at 41C for 5 min. The pellet was washed twice in NP40 buffer. Nuclei were then lysed in nuclear extraction buffer (20 mM HEPES, pH 7.9, 25% glycerol, 0.42 mM NaCl, 1.5 mM MgCl 2 , 0.2 mM EDTA, 0.5 mM phenylmethylsulfonyl fluoride and 0.5 mM DTT) and sonicated 10 s at 41C. The protein concentration was determined using the Bio-Rad protein assay. The nuclear proteins were frozen at À801C. Both buffers contained the complete protease inhibitor cocktail tablets from Roche. Nuclear protein (5 mg) was mixed for 30 min at room temperature with biotin-labeled oligonucleotide probe NF-kB and YY1 using the EMSA Kit purchased from Panomicst (AY1030, AY1028; Panomics Inc., Redwood City, CA, USA), following the manufacturer's instructions. A measure of 10 ml was subjected to 5% polyacrylamide gel electrophoresis for 90 min in TBE buffer (Bio-Rad Laboratories), and transferred to Nylon transfer membrane Hybond-N þ (Amersham) using the Trans-Blot s SD semidry Transfer cell System (Bio-Rad). The membranes were transferred to a UV crosslinker FB-UVXL-1000 Fisher technology (Fisher Scientific) for 3 min. The detection was made as per the manufacturer's instructions and the membranes were exposed using Hyperfilm ECL (Amersham Pharmacia Biotech).
Isobologram analysis for synergy
To establish whether the cytotoxic effect of the combination of rituximab and CH-11 antibody was more than additive, isobolograms (Berenbaum, 1981) were developed from a battery of combinations of rituximab used at various concentrations (10, 20 and 40 mg/ml) with anti-Fas antibody CH-11 (5, 10 and 20 ng/ml). Combinations yielding 3075% cytotoxicity were plotted as percentage of single agent alone that resulted in the same percentage of cytotoxicity (fractional inhibitory concentration: concentration of each agent in combination/concentration of each agent alone). When the sum of this fraction (fractional inhibitory concentration) is 1, the combination is additive and the graph is geometrically expressed as a straight line; when the sum is o1, the combination is synergistic and the graph appears as concave shape; and when the sum is >1, the combination is antagonistic and the graph is geometrically represented as convex shape.
Statistical analysis
All results were expressed as the mean7s.d. of data obtained from three to four separate experiments. The statistical significance of differences between group means was determined using one-way ANOVA to compare variance. Significant differences were considered for probabilities o5% (Po0.05).
Abbreviations ADCC, antibody-dependent cellular cytotoxicity; ATCC, American Tissue Cell Collection; Bay 11-7085, (E)3-[(4-tbutylphenyl)sulfonyl]-2-propenenitrile; Bcl-2, B-cell leukemia
